TerminatedNo phase
A Long-term Follow-up Study of Patients Who Received VOR33
Reason given: Lack of Funding
Key facts
- Where
- Bethesda, Cleveland, Hackensack, La Jolla, Miami, New York, Seattle, and St Louis, United StatesSee the 10 sites
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesNo longer taking part
- University Hospitals Seidman Cancer CenterCleveland, United StatesNo longer taking part
- John Theurer Cancer Center at Hackensack University Medical CenterHackensack, United StatesNo longer taking part
- University of California San Diego Moores Cancer CenterLa Jolla, United StatesNo longer taking part
- Miami Cancer InstituteMiami, United StatesNo longer taking part
- Columbia University Medical Center - Herbert Irving Comprehensive Cancer CenterNew York, United StatesNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- Fred Hutchinson Cancer Research CenterSeattle, United StatesNo longer taking part
- Washington University School of Medicine - Siteman Cancer CenterSt Louis, United StatesNo longer taking part
Trial details
- Who runs it
- Vor Biopharma
- Trial code
- NCT05309733
- Record updated
- 29 July 2025
- Original description
VOR33 long-term follow-up (LTFU) studyRead full original descriptionShow less
VOR33 long-term follow-up (LTFU) study
Inclusion: A patient is included in this study if he/she:; Has received any part of or all of a VOR33 infusion.
Exclusion: There are no exclusion criteria.